The efficacy, functions and side effects of venetoclax/venetoclax tablets

Venetoclax/Venetoclax is a new type of targeted therapy drug that has shown excellent results in targeting B-cell lymphoma factor-2 (BCL-2). Venetoclax is an oral drug and a BCL-2 protein inhibitor. The main functions and effects of this drug, as well as possible side effects are as follows:

Veneclat promotes leukemia cell apoptosis (cell death) by inhibiting the activity ofBCL-2 protein. BCL-2 is a protein that inhibits apoptosis. Overexpression of BCL-2 will cause leukemia cells to be unable to die on their own. Venetoclax works by restoring the normal regulatory mechanism of apoptosis, thereby reducing the growth of leukemia cells. Veneclat has demonstrated significant efficacy in patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It can improve patient survival, extend progression-free survival, and achieve complete remission in some cases. Venetoclax is an oral medication that patients can take at home, avoiding the need for hospitalization or other complex treatments.

Although venetoclax is effective in treating leukemia, it can also cause some side effects. Of these, the most common is infection. Because venetoclax may affect the function of the immune system, leading to neutropenia and reduced immunity, patients may be more susceptible to infections. In addition, gastrointestinal reactions are also common side effects, including nausea, vomiting, diarrhea, and abdominal pain. There are also possible drug interactions to be aware of when using venetoclax. In particular, it cannot be used together with strong CYP3A inhibitors, because this may increase the concentration of the drug in the body, thereby increasing the risk of side effects, and may even cause tumor lysis syndrome, causing hyperuricemia, hypocalcemia and other conditions.